Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy consists of **budesonide**, a synthetic glucocorticoid corticosteroid, and **lidocaine**, a local anesthetic of the amide type. It is being investigated by **Qianfoshan Hospital** for the prevention and treatment of postoperative sore throat (POST) in patients undergoing thyroidectomy with nerve monitoring. Budesonide acts as an anti-inflammatory agent by binding to glucocorticoid receptors, thereby reducing mucosal edema and inflammation caused by tracheal intubation and surgical positioning. Lidocaine provides local anesthesia by blocking voltage-gated sodium channels, which inhibits the conduction of pain impulses from the laryngeal and tracheal mucosa. The combination is administered via glottic nebulization to provide targeted, non-invasive relief at the site of potential injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on budesonide + lidocaine.